Literature DB >> 12843074

Evaluation of the editing process in human immunodeficiency virus type 1 genotyping.

Diana D Huang1, Susan H Eshleman, Donald J Brambilla, Paul E Palumbo, James W Bremer.   

Abstract

Sequencing-based human immunodeficiency virus type 1 (HIV-1) genotyping assays require subjective interpretation (editing) of sequence data from multiple primers to form consensus sequences and identify antiretroviral drug resistance mutations. We assessed interlaboratory variations in editing and their impact on the recognition of resistance mutations. Six samples were analyzed in a central laboratory by using a research-use-only HIV-1 genotyping system previously produced by Applied Biosystems. The electronic files of individual primer sequences from the samples were sent to 10 laboratories to compare sequence editing strategies. Each sequence data set included sequences from seven primers spanning protease codons 1 to 99 and reverse transcriptase codons 1 to 320. Each laboratory generated a consensus sequence for each sample and completed a questionnaire about editing strategy. The amount of editing performed, the concordance of consensus sequences among the laboratories, and the identification of resistance mutations were evaluated. Sequence agreement was high among the laboratories despite wide variations in editing strategies. All laboratories identified 66 (88%) of 75 resistance mutations in the samples. Nonconcordant identifications were made for 9 (12%) of the 75 mutations, all of which required editing for identification. These results indicate a need for standardized editing guidelines in genotyping assays. Proficiency in editing should be assessed in training and included in quality control programs for HIV-1 genotyping.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843074      PMCID: PMC165383          DOI: 10.1128/JCM.41.7.3265-3272.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.

Authors:  M C Weinstein; S J Goldie; E Losina; C J Cohen; J D Baxter; H Zhang; A D Kimmel; K A Freedberg
Journal:  Ann Intern Med       Date:  2001-03-20       Impact factor: 25.391

Review 2.  Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals.

Authors:  F Romanelli; C Pomeroy
Journal:  Pharmacotherapy       Date:  2000-02       Impact factor: 4.705

3.  Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; J Martinez-Picado; L Sutton; J D Hazelwood; R T D'Aquila
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

Review 4.  Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV.

Authors:  M Arens
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

5.  Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.

Authors:  M Erali; S Page; L G Reimer; D R Hillyard
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

6.  Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  R Schuurman; L Demeter; P Reichelderfer; J Tijnagel; T de Groot; C Boucher
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

Review 7.  Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.

Authors:  G J Hanna; R T D'Aquila
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

8.  Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.

Authors:  P Clevenbergh; J Durant; P Halfon; P del Giudice; V Mondain; N Montagne; J M Schapiro; C A Boucher; P Dellamonica
Journal:  Antivir Ther       Date:  2000-03

9.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

10.  The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

Authors:  V DeGruttola; L Dix; R D'Aquila; D Holder; A Phillips; M Ait-Khaled; J Baxter; P Clevenbergh; S Hammer; R Harrigan; D Katzenstein; R Lanier; M Miller; M Para; S Yerly; A Zolopa; J Murray; A Patick; V Miller; S Castillo; L Pedneault; J Mellors
Journal:  Antivir Ther       Date:  2000-03
View more
  20 in total

1.  Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Authors:  Conan K Woods; Chanson J Brumme; Tommy F Liu; Celia K S Chui; Anna L Chu; Brian Wynhoven; Tom A Hall; Christina Trevino; Robert W Shafer; P Richard Harrigan
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010.

Authors:  Neil Parkin; James Bremer; Silvia Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

3.  Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network.

Authors:  Neil Parkin; Carmen de Mendoza; Rob Schuurman; Cheryl Jennings; James Bremer; Michael R Jordan; Silvia Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

4.  High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity.

Authors:  Avelin F Aghokeng; Eitel Mpoudi-Ngole; Julius E Chia; Elvine M Edoul; Eric Delaporte; Martine Peeters
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

5.  Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.

Authors:  Sihong Xu; Jingyun Li; Zuoyi Bao; Hui Xing; Ping Zhong; Hanping Li; Haiwei Zhou; Xinping Li; Sharon Wu; Aijing Song; Xiuhua Li; Jianhui Nie; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

6.  Comparative evaluation of the ViroSeq™ HIV-1 genotyping system and an in-house method for analysis of HIV-1 drug-resistance mutations in China.

Authors:  Sihong Xu; Ping Zhong; Jingyun Li; Aijing Song; Hanping Li; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

7.  Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase.

Authors:  Allison K Delong; Mingham Wu; Diane Bennett; Neil Parkin; Zhijin Wu; Joseph W Hogan; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-26       Impact factor: 2.205

8.  Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays.

Authors:  Diana D Huang; James W Bremer; Donald J Brambilla; Paul E Palumbo; Grace Aldrovandi; Susan Eshleman; Clark Brown; Susan Fiscus; Lisa Frenkel; Hasnah Hamdan; Stephen Hart; Andrea Kovacs; Paul Krogstad; Phillip LaRussa; John Sullivan; Adriana Weinberg; Yu Qi Zhao
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

9.  Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.

Authors:  Shigeru Yoshida; Junko Hattori; Masakazu Matsuda; Kiyomi Okada; Yukumasa Kazuyama; Osamu Hashimoto; Shiro Ibe; Shin-ichi Fujisawa; Hitoshi Chiba; Masashi Tatsumi; Shingo Kato; Wataru Sugiura
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-03       Impact factor: 2.205

10.  TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.

Authors:  Sally Land; Philip Cunningham; Jialun Zhou; Kevin Frost; David Katzenstein; Rami Kantor; Yi-Ming Arthur Chen; Shinichi Oka; Allison DeLong; David Sayer; Jeffery Smith; Elizabeth M Dax; Matthew Law
Journal:  J Virol Methods       Date:  2009-03-26       Impact factor: 2.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.